Cargando…
STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma
Primary mediastinal B-cell lymphoma (PMBCL) is the only non-Hodgkin’s lymphoma variant responding to immune checkpoint inhibitor (ICI) therapy, approximately in half of the cases; however, no molecular markers predicting a response to ICI therapy in PMBCL have been described so far. In this study, w...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139229/ https://www.ncbi.nlm.nih.gov/pubmed/35621668 http://dx.doi.org/10.3390/curroncol29050278 |
_version_ | 1784714810452082688 |
---|---|
author | Risinskaya, Natalya Mangasarova, Yana Nikulina, Elena Kozhevnikova, Yana Chabaeva, Julia Yushkova, Anna Magomedova, Aminat Kulikov, Sergey Julhakyan, Hunan Kravchenko, Sergey Sudarikov, Andrey |
author_facet | Risinskaya, Natalya Mangasarova, Yana Nikulina, Elena Kozhevnikova, Yana Chabaeva, Julia Yushkova, Anna Magomedova, Aminat Kulikov, Sergey Julhakyan, Hunan Kravchenko, Sergey Sudarikov, Andrey |
author_sort | Risinskaya, Natalya |
collection | PubMed |
description | Primary mediastinal B-cell lymphoma (PMBCL) is the only non-Hodgkin’s lymphoma variant responding to immune checkpoint inhibitor (ICI) therapy, approximately in half of the cases; however, no molecular markers predicting a response to ICI therapy in PMBCL have been described so far. In this study, we assessed the incidence of the loss of heterozygosity (LOH), elevated microsatellite alteration at selected tetranucleotides (EMAST), and microsatellite instability (MSI) in the tumor genomes of 72 patients with PMBCL undergoing high-dose chemotherapy treatment at the National Research Center for Hematology (Moscow, Russia). Tumor DNA was isolated from biopsy samples taken at diagnosis. Control DNA was isolated from the blood of patients in complete remission or from buccal epithelium. STR-profiles for LOH and EMAST were assessed by PCR with COrDIS Plus multiplex kit (Gordiz Ltd., Moscow, Russia). LOH was detected in 37 of 72 patients (51.4%). EMAST was found in 40 patients (55.5%); 24 had a combination of EMAST with LOH. MSI-high was not found, while MSI-low was detected only in one patient. The association of certain genetic lesions with the clinical outcome in patients receiving treatment according to the standard clinical protocol R-Da-EPOCH-21 has been estimated (58 patients out of 72) and no associations with the worst overall or event-free survival were found. |
format | Online Article Text |
id | pubmed-9139229 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91392292022-05-28 STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma Risinskaya, Natalya Mangasarova, Yana Nikulina, Elena Kozhevnikova, Yana Chabaeva, Julia Yushkova, Anna Magomedova, Aminat Kulikov, Sergey Julhakyan, Hunan Kravchenko, Sergey Sudarikov, Andrey Curr Oncol Article Primary mediastinal B-cell lymphoma (PMBCL) is the only non-Hodgkin’s lymphoma variant responding to immune checkpoint inhibitor (ICI) therapy, approximately in half of the cases; however, no molecular markers predicting a response to ICI therapy in PMBCL have been described so far. In this study, we assessed the incidence of the loss of heterozygosity (LOH), elevated microsatellite alteration at selected tetranucleotides (EMAST), and microsatellite instability (MSI) in the tumor genomes of 72 patients with PMBCL undergoing high-dose chemotherapy treatment at the National Research Center for Hematology (Moscow, Russia). Tumor DNA was isolated from biopsy samples taken at diagnosis. Control DNA was isolated from the blood of patients in complete remission or from buccal epithelium. STR-profiles for LOH and EMAST were assessed by PCR with COrDIS Plus multiplex kit (Gordiz Ltd., Moscow, Russia). LOH was detected in 37 of 72 patients (51.4%). EMAST was found in 40 patients (55.5%); 24 had a combination of EMAST with LOH. MSI-high was not found, while MSI-low was detected only in one patient. The association of certain genetic lesions with the clinical outcome in patients receiving treatment according to the standard clinical protocol R-Da-EPOCH-21 has been estimated (58 patients out of 72) and no associations with the worst overall or event-free survival were found. MDPI 2022-05-10 /pmc/articles/PMC9139229/ /pubmed/35621668 http://dx.doi.org/10.3390/curroncol29050278 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Risinskaya, Natalya Mangasarova, Yana Nikulina, Elena Kozhevnikova, Yana Chabaeva, Julia Yushkova, Anna Magomedova, Aminat Kulikov, Sergey Julhakyan, Hunan Kravchenko, Sergey Sudarikov, Andrey STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma |
title | STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma |
title_full | STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma |
title_fullStr | STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma |
title_full_unstemmed | STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma |
title_short | STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma |
title_sort | str profiling reveals tumor genome instability in primary mediastinal b-cell lymphoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139229/ https://www.ncbi.nlm.nih.gov/pubmed/35621668 http://dx.doi.org/10.3390/curroncol29050278 |
work_keys_str_mv | AT risinskayanatalya strprofilingrevealstumorgenomeinstabilityinprimarymediastinalbcelllymphoma AT mangasarovayana strprofilingrevealstumorgenomeinstabilityinprimarymediastinalbcelllymphoma AT nikulinaelena strprofilingrevealstumorgenomeinstabilityinprimarymediastinalbcelllymphoma AT kozhevnikovayana strprofilingrevealstumorgenomeinstabilityinprimarymediastinalbcelllymphoma AT chabaevajulia strprofilingrevealstumorgenomeinstabilityinprimarymediastinalbcelllymphoma AT yushkovaanna strprofilingrevealstumorgenomeinstabilityinprimarymediastinalbcelllymphoma AT magomedovaaminat strprofilingrevealstumorgenomeinstabilityinprimarymediastinalbcelllymphoma AT kulikovsergey strprofilingrevealstumorgenomeinstabilityinprimarymediastinalbcelllymphoma AT julhakyanhunan strprofilingrevealstumorgenomeinstabilityinprimarymediastinalbcelllymphoma AT kravchenkosergey strprofilingrevealstumorgenomeinstabilityinprimarymediastinalbcelllymphoma AT sudarikovandrey strprofilingrevealstumorgenomeinstabilityinprimarymediastinalbcelllymphoma |